Translocation of Clostridium perfringens after administration of OKT3.
Bonventre
E V
EV
Harberts
S
S
Waymack
J P
JP
Bowman
J S
JS
Jaffers
G
G
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology; D017252:CD3 Complex; D003015:Clostridium Infections / Q000276:immunology*; D003016:Clostridium perfringens; D005260:Female; D006801:Humans; D016853:Muromonab-CD3; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D018805:Sepsis / Q000209:etiology*
D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D016853:Muromonab-CD3; D011948:Receptors, Antigen, T-Cell